To see the other types of publications on this topic, follow the link: B Congresses.
Journal articles on the topic 'B Congresses'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'B Congresses.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Ferguson, M. K. "ISDE Presidential Biography: David B. Skinner, MD." Diseases of the Esophagus 32, no. 10 (October 2019): 1–2. http://dx.doi.org/10.1093/dote/doz054.
Full textAbstract:
SUMMARY Dr. David Skinner, the 4th President of the ISDE, was a world-renowned surgeon, educator, scholar, and leader. He participated in the formation of the ISDE, hosted two international congresses in 1983 and 1989, and made important advances in the ISDE during his presidential tenure 1992–1995.
2
Costa, Mia, Jill S. Greenlee, Tatishe Nteta, Jesse H. Rhodes, and Elizabeth A. Sharrow. "Family Ties? The Limits of Fathering Daughters on Congressional Behavior." American Politics Research 47, no. 3 (February 4, 2019): 471–93. http://dx.doi.org/10.1177/1532673x19826273.
Full textAbstract:
Scholars have long suggested that familial life can affect political behavior and, more recently, have found that fathering daughters leads men to adopt more liberal positions on gender equality policies. However, few have focused on the impact of fathering a daughter on congressional behavior, particularly in an era of heightened partisan polarization. Using an original data set of familial information, we examine whether fathering a daughter influences male legislators’ (a) roll call and cosponsorship support for women’s issues in the 110th to 114th Congresses and (b) cosponsorship of bills introduced by female legislators in the 110th Congress. We find that once party affiliation is taken into account, having a daughter neither predicts support for women’s issues nor cosponsorship of bills sponsored by women. Our findings suggest there are limits to the direct effects of parenting daughters on men’s political behavior, and that scholars should remain attentive to institutional and partisan contexts.
3
Grupper, Emmanuel, Alexander Schneider, and Friedhelm Peters. "INTRODUCTION TO SPECIAL ISSUE: AN EMPIRICAL EXPLORATION OF CHILD AND YOUTH CARE PEDAGOGY AND CURRICULUM." International Journal of Child, Youth and Family Studies 11, no. 4 (November 18, 2020): 1–6. http://dx.doi.org/10.18357/ijcyfs114202019935.
Full textAbstract:
FICE International is an international organization focused on children and youth who are in need of out-of-home care. One of its major activities is organizing a world congress every three years. In these congresses, professionals from all over the world who are involved with out-of-home care can meet, exchange knowledge, and learn from each other. The most recent FICE congress, held in October 2019 in Tel Aviv, Israel, was dedicated to the theme “Better Future Opportunities for Children and Young People in Multicultural Societies”. The editor of this journal has been kind enough to offer this platform for the publication of selected material presented at the congress. FICE-International, and we as guest editors, are most thankful to Prof. Sibylle Artz, editor of the IJCYFS, for this opportunity. The richness and variety of the selected articles, coming from 10 countries, could not be accommodated in a single issue. The editors of the journal have therefore decided to divide the articles into two special issues, to be published one after the other. The first of these issues includes articles in three thematic categories: (a) Evidence-based research on effects of out-of-home care, (b) Historical and sociological perspectives on institutionalized child and youth care, and (c) Normalization — a challenge for foster care programs. Four further categories will provide the framework for the forthcoming second special issue: (d) Emotional and pedagogical considerations, (e) Refugee children and youth, (f) Residential staff, and (g) Care leavers.
4
J. Connolly and International College of Psychosomatic Medicine. "The 10th and 11th world congresses of the international college of psychosomatic medicine. Report and announcement." Journal of Psychosomatic Research 34, no. 3 (January 1990): 352–53. http://dx.doi.org/10.1016/0022-3999(90)90103-b.
Full text
5
Haron, Muhammed. "Second International Congress on Islamic Civilization in Southern Africa." American Journal of Islam and Society 33, no. 3 (July 1, 2016): 150–54. http://dx.doi.org/10.35632/ajis.v33i3.931.
Full textAbstract:
In 2006 the first International Congress of Islamic Civilization in SouthernAfrica was hosted by AwqafSA (www.awqafsa. org.za) and IRCICA (Centrefor Islamic History, Art, and Culture www.ircica.org) at the University of Johannesburg.IRCICA, the prime mover and funder of this and similar conferencesand congresses worldwide, has been actively promoting these platformsto bring academics, scholars, researchers, and other stakeholders together tohighlight research outputs and findings that reflect upon the status and positionof Muslim minorities worldwide. Since Southern African Muslim communitiesform an integral part of Africa’s Muslims, it decided to host a follow-upevent in the region.IRCICA once again teamed up with AwqafSA, which had been in closecontact with IRCICA since the 2003 Uganda “Islamic Civlization in EastAfrica” conference. For this congress, AwqafSA partnered with the InternationalPeace College of South Africa (IPSA) and the University of KwaZulu-Natal (UKZN). It also teamed up with ITV, Radio Al-Ansaar, and the MinaraChamber of Commerce. Since UKZN was the main academic partner, thecongress was held from March 4-6, 2016, at the Senate Chambers of UKZN’sWestville campus.The organizers’ objectives for the congress were to (a) increase people’sknowledge of the history and heritage of Southern Africa’s Muslims, (b)strengthen cooperation among Muslim and African nations and their peoplesby producing and disseminating Islamic and cultural knowledge, and (c) offera forum for the true understanding of Islamic culture in the world.Donal McCracken (acting dean of research, College of Humanities) officiallywelcomed the delegates. Following his opening remarks, the audienceheard from the representatives of the Congress Organizing Committee.Zeinoul Cajee (CEO, AwqafSA), Halit Eren (director-general, IRCICA), andShaykh Ighsaan Taliep (IPSA). Eren underscored the importance of these ...
6
Capraru, Annina, Luigi Raio, Martin Müller, Michael Daskalakis, Alicia Rovo, Hustinx Christian Henri, McDougall Jane, Sacha Sergio Zeerleder, and Behrouz Teleghani Mansouri. "Immunoadsorption, Intravenous Immunoglobulins and Rituximab (IIR): Successful New Treatment Approach for Severe Anti K- Alloimmunisation during Pregnancy." Blood 136, Supplement 1 (November 5, 2020): 16–17. http://dx.doi.org/10.1182/blood-2020-140558.
Full textAbstract:
Background: Fetal red blood cells (RBC), erythroid and megakaryopoietic progenitor cells start to express the Kell (K) antigen already during the 10th gestational week (GW). Maternal anti-Kell alloimmunization (allo-anti-K-Ab) causes early (< 20th GW) and severe hemolytic disease of the fetus/newborn (HDFN) accompanied by erythroaplasia and potential thrombocytopenia. Therefore, prevention/delay of HDFN is highly relevant. Current treatment options include intra-uterine transfusions (IUT) of the fetus in case of suspected anemia, i.v. high-dose immunoglobulins (IVIG), plasma exchange and immunoadsorption (IA). Their efficacy often remains unsatisfactory and procedure related complications might occur. We present our new triple-treatment approach, combining IA + IVIG + Rituximab (Rtx) (IIR), which we successfully applied in 2 high-risk patients with allo-anti-K-Ab. Methods: The first patient was a 24 y, para 1, gravida 2, with an allo-anti-K-AB titer of 1:2000 in the 15th GW, at first presentation. Duplex-sonography showed no signs of fetal anemia. The second patient was a 40 y para 1, gravida 2. She presented with an allo-anti-K-Ab titer of 1:8000 in the 20th GW. Duplex-sonography revealed signs of severe anemia of fetus, requiring immediate IUT. Fetal K- genotyping (RT-PCR) using cell-free fetal DNA from maternal plasma confirmed a K- positive status in both fetuses. Duplex sonography monitoring was executed weekly, including the assessment of arteria cerebri media peak systolic velocity (ACM PSV). After having received informed consent of patients, we started the treatment at 14th and 21st GW in our first and second patient, respectively. IIR treatment cycles (1 cycle = 21 days) comprised 6x IA (each processing 2x the patient's plasma volume, weeks 1 + 2, every other day), followed by IVIG (1g/kg body weight) and i.v. Rtx (375 mg/m2) after the last IA of each cycle. This resulted in a total of 6 and 5 cycles for the first and second patient, respectively. We omitted Rtx for the last cycles in both patients. Results: IIR treatment resulted in a significant reduction of maternal anti K-titer to minimum of 1:32 in both patients, with a fluctuating course. In case 1 we performed a cordocentesis in the 30th GW because of an increased ACM PSV. The blood count of the fetus showed no anemia (Hb: 132 g/L) and only minimal Thrombocytopenia (145 G/L). The fetus in case 2 had already duplex- sonographic signs for a severe anemia at first presentation. Diagnostic cordocentesis confirmed a severe anemia (Hb 47 g/L) and also severe thrombocytopenia (21 G/L). Fetal alloimmune thrombocytopenia was ruled out. The first IUT of RBC has been performed right before starting IIR. Two weeks later a second IUT of RBC was necessary (fetal Hb 54 g/L), but thrombocytopenia was completely reversed (Tc: 352 G/l). The third and last IUT of RBC was performed 5 weeks later (Hb 99 g/L). Thereafter, no other signs of fetal anemia were detected. Patient one showed nausea/headache after her first IVIG-application and hypotonia/sinustachykardia during IA of the 5th cycle. IIR-treatment and IUT revealed no further adverse events. We continued treatment in both cases until the 32nd GW. Both neonates were born healthy in the 38th and 37th GW, respectively. The neonate in case 1 presented a mild anemia (Hb: 131 g/l), but normalized his Hb from 2nd day onwards. Both newborns showed a positive direct antiglobulin test (DAT), elution verified an anti-K-Ab, and their RBC were serologically positive for K. Both cases had normal Bilirubin and LDH levels, but a haptoglobin <0.1 g/l at birth. Both developed an icterus neonatorum during the first days after birth and needed phototherapy, Hb remained normal at all times. Flow cytometry of fetal lymphocytes showed a B-cell decrease (5.2%) in the first case and completely missing B-cells in the second case. Rtx level was low (2.13 µg/ml) in maternal plasma and neg. in the newborn of the first case. In the second case Rtx levels of the newborn and mother were 15,87 µg/ml and 4,5 µg/ml, respectively. In both cases, breastmilk showed no Rtx but positivity for anti-K-Ab (IgG). We observed no hemolysis of the newborns, while both were on breastfeeding. Conclusion: High-titer anti-Kell alloimmunisation causes early onset and severe HDFN and may be associated with severe thrombocytopenia. Treatment of affected pregnant women by using the Bern IIR-protocol was effective and safe in both severely affected patients. Disclosures Rovo: Novartis:Honoraria, Research Funding;CSL Behring:Research Funding;AG Alexion:Research Funding;Celgene:Honoraria, Other: financial support for congresses and conferences travel;BMS:Other: financial support for congresses and conferences travel;AstraZeneca:Other: financial support for congresses and conferences travel;Sanofi:Other: financial support for congresses and conferences travel;Amgen:Other: financial support for congresses and conferences travel;Roche:Other: financial support for congresses and conferences travel. OffLabel Disclosure: Rituximab is used for B-cell depletion in different malignant and non-malignant diseases. The off-label use concerns ist use in pregnant women with alloimmunisation.
7
Shapiro, Amy, Giancarlo Castaman, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, Silva Zupancic-Salek, and Victor Jimenez-Yuste. "Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial." Blood 134, Supplement_1 (November 13, 2019): 1139. http://dx.doi.org/10.1182/blood-2019-122809.
Full textAbstract:
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia patients. We present results from the main part (at least 24 weeks) of the concizumab explorer4 phase 2 trial (NCT03196284) in hemophilia A/B with inhibitor (HAwI/HBwI) patients. Methods The primary objective was to assess the efficacy of once-daily subcutaneous concizumab in preventing bleeds in HAwI/HBwI patients. Secondary objectives were the assessment of safety, including concomitant use of recombinant activated factor VII (rFVIIa), and immunogenicity. Patients were randomized 2:1 to concizumab prophylaxis or rFVIIa on-demand treatment via an interactive web-response system. A concizumab loading dose (0.5 mg/kg) was administered, followed by 0.15 mg/kg daily with potential dose escalation to 0.20 and 0.25 mg/kg. Efficacy was evaluated as the number of bleeding episodes (annualized bleeding rate [ABR]) at last dose level. The number of adverse events (AEs) and the occurrence of anti-drug antibodies (ADAs), as well as coagulation-related parameters were evaluated. Concizumab and free TFPI plasma levels were measured by ELISA, and peak thrombin generation (TG) potential using a standardized assay. Results 26 patients were randomized; 9 HAwI and 8 HBwI patients were exposed to concizumab, and 9 patients to rFVIIa (7 with HAwI and 2 with HBwI). All 25 patients who completed the main 24-week part of the trial chose to continue to the extension part. The estimated ABR at the last dose level for concizumab prophylaxis was 4.5 (95% CI: 3.2−6.4) and for rFVIIa on demand, 20.4 [95% CI: 14.4−29.1] (Figure 1). There was a 78, 88 and 79% reduction in all treated bleeds and in spontaneous and joint bleeds, respectively, with concizumab prophylaxis compared with on-demand treatment (Figure 1). Concizumab concentration varied considerably between patients on the same dose level. Increasing concizumab dose was associated with lower free TFPI and normalized TG potential (Figure 2). No deaths, thromboembolic events or AE-related withdrawals occurred. No safety concerns with concomitant use of concizumab and rFVIIa were identified. Three patients had positive (very-low to medium-titer) ADA tests (titer range: 1 to 128), but with no apparent clinical effect. As expected, elevated prothrombin fragment 1+2 and D-dimers were observed across all concizumab dose levels, reflecting the hemostatic effect of concizumab. Conclusions In the phase 2 explorer4 trial, concizumab was efficacious and safe as a subcutaneous prophylactic treatment in HAwI patients, as well as in HBwI patients for whom there is currently no prophylactic regimen available. There was no difference in safety and efficacy across hemophilia subtypes, including with the concomitant use of concizumab and the bypassing agent rFVIIa. The phase 2 trial results, which include the explorer5 trial in HA without inhibitors, support further development of concizumab as a prophylactic treatment for all hemophilia patients and have guided selection of the phase 3 dosing regimen. Disclosures Shapiro: Sangamo Biosciences Inc: Consultancy, Other: Clinical Research Protocol with the company; Genentech: Membership on an entity's Board of Directors or advisory committees, Other: Clinical Research Protocol with the company; Novo Nordisk Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Clinical Research Protocol with the company; Bioverativ: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Clinical Research Protocol with the company; OPKO: Other: Clinical Research Protocol with the company; Octapharma: Other: Clinical Research Protocol with the company; Prometic Life Sciences: Consultancy; Shire/Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Clinical Research Protocol with the company, Research Funding; Bayer: Other: Clinical Research Protocol with the company; Kedrion Biopharma: Other: Clinical Research Protocol with the company; Agios: Other: Clinical Research Protocol with the company; Prometic Bio Therapeutics: Other: Clinical Research Protocol with the company; BioMarin: Other: Clinical Research Protocol with the company; Daiichi Sankyo: Other: Clinical Research Protocol with the company; Glover Blood Therapeutics: Other: Clinical Research Protocol with the company; Novartis: Other: Clinical Research Protocol with the company; Pfizer: Other: Clinical Research Protocol with the company; American Thrombosis and Hemostasis Network: Membership on an entity's Board of Directors or advisory committees. Castaman:Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kedrion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Research Funding; Sobi: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; CSL Behring: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Uniqure: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Werfen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda (SHIRE): Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Cepo:Novo Nordisk A/S: Employment. Hvitfeldt Poulsen:Novo Nordisk: Other: Clinical trials - investigator, Funding meetings and congresses; Bayer Health Care: Other: Clinical trials - investigator, Funding meetings and congresses; Pfizer: Other: Funding meetings and congresses; Sobi: Other: Funding meetings and congresses. Hollensen:Novo Nordisk: Employment. Matsushita:Bioverative: Research Funding; Pfizer: Consultancy, Honoraria; KM biologists: Consultancy, Honoraria, Research Funding; Novo Nordisk: Consultancy, Honoraria; CSL: Consultancy, Honoraria; uniQure: Consultancy, Honoraria. Young:Bioverativ/Sanofi: Consultancy, Honoraria; CSL Behring: Consultancy, Honoraria; Freeline: Consultancy, Honoraria; Genentech/Roche: Consultancy, Honoraria, Research Funding; Grifols: Consultancy, Honoraria; Kedrion: Consultancy, Honoraria; Novo Nordisk: Consultancy, Honoraria; Spark: Consultancy, Honoraria; Shire/Takeda: Consultancy, Honoraria; Uniqure: Consultancy, Honoraria. Zupancic-Salek:Novo Nordisk: Consultancy, Honoraria, Speakers Bureau; Biogen: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau. Jimenez-Yuste:Bayer, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Shire: Consultancy, Honoraria, Other: reimbursement for attending symposia/congresses , Research Funding, Speakers Bureau.
8
Sapozhnykov, І. V. "THE KURGANS OF BUDZHAK EXPLORED BY F. I. KNAUER: HISTORY OF EXCAVATION, CARTOGRAPHY AND MODERN STATE." Archaeology and Early History of Ukraine 33, no. 4 (December 25, 2019): 396–422. http://dx.doi.org/10.37445/adiu.2019.04.32.
Full textAbstract:
The article is observed the archeological activity of the native of German colony of Sarata in Budzhak and the author of first excavations of the barrows of this region, Professor F. I. Knauer. Fedor (Friedrich) Ivan Knauer (1849—1917) graduated the Sarata Teachers College (1865). He studied linguistics, Sanskrit and German at the Universities of Jena and Tubingen, graduated the University of Derpt (1882) where he defended his doctoral thesis (1884). After that he worked at St. Vladimir University in Kiev as Professor of the Department of Comparative Linguistics and Sanskrit (from 1886 to 1915). He participated the XI Archaeological Congress in Kiev (1899), XIII (1902, Hamburg) and XVI (1912, Athens) international congresses of orientalists.
The scholar engaged in archaeology under the influence of members of the Historical Society of Nestor the Chronist, in particular Professor V. B. Antonovich. One of his tasks was to gather the collection for the creation of the archaeological museum at St. Vladimir’s University. The fieldwork of the scholar in 1888—1889, 1891, and 1899 are described in the paper. During these works he examined 11 barrows on the banks of the rivers Sarat and Kogylnik and found 75—77 graves which were compiled to the chrono-stratigraphic column of burials from the Eneolithic to the Middle Ages. In the special annex to the paper the materials of research of the author of 2018 were revealed, during which the state of the majority of thebarrows of F. I. Knauer was discovered and some of which are proposed to be excavated
9
Elliott, Paul. "Louise Miskell, Meeting Places: Scientific Congresses and Urban Identity in Victorian Britain. Farnham: Ashgate, 2013. 204pp. 14 b&w illustrations. £60.00." Urban History 41, no. 1 (January 9, 2014): 167–69. http://dx.doi.org/10.1017/s096392681300093x.
Full text
10
Veyssière, Hugo, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, and Xavier Durando. "XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer." F1000Research 9 (October 9, 2020): 1219. http://dx.doi.org/10.12688/f1000research.26873.1.
Full textAbstract:
Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX from primitive mammary tumours or after neoadjuvant treatment are still rare. This study aims to assess the feasibility to establish xenografts from tumour samples of patients with triple negative or luminal B breast cancer in neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a single-centre and prospective study. This feasibility pilot trial aims to produce xenografts from tumour samples of patients with triple negative or luminal B breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be enrolled and followed for 28 months. Additional blood samples will be taken as part of the study. Surgical specimens from post-NAC surgery, primary surgery or surgical excision of the metastases will be collected to establish PDX. Histomolecular characteristics of the established PDX will be investigated and compared with the initial histomolecular profile of the collected tumours to ensure that they are well-established. Ethics and dissemination: XENOBREAST belongs to category 2 interventional research on the human person. This study has been approved by the Sud Méditerranée IV – Montpellier ethics committee. It is conducted notably in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study data and findings will be published in peer-reviewed medical journals. We also plan to present the study and all data at national congresses and conferences. Registration: ClinicalTrials.gov ID NCT04133077; registered on October 21, 2019.
11
Veyssière, Hugo, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, and Xavier Durando. "XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer." F1000Research 9 (March 10, 2021): 1219. http://dx.doi.org/10.12688/f1000research.26873.2.
Full textAbstract:
Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX from primary mammary tumours or after neoadjuvant treatment are still rare. This study aims to assess the feasibility to establish xenografts from tumour samples of patients with triple negative or luminal B breast cancer in neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a single-centre and prospective study. This feasibility pilot trial aims to produce xenografts from tumour samples of patients with triple negative or luminal B breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be enrolled and followed for 28 months. Additional blood samples will be taken as part of the study. Surgical specimens from post-NAC surgery, primary surgery or surgical excision of the metastases will be collected to establish PDX. Histomolecular characteristics of the established PDX will be investigated and compared with the initial histomolecular profile of the collected tumours to ensure that they are well-established. Ethics and dissemination: XENOBREAST belongs to category 2 interventional research on the human person. This study has been approved by the Sud Méditerranée IV – Montpellier ethics committee. It is conducted notably in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study data and findings will be published in peer-reviewed medical journals. We also plan to present the study and all data at national congresses and conferences. Registration: ClinicalTrials.gov ID NCT04133077; registered on October 21, 2019.
12
Veyssière, Hugo, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, and Xavier Durando. "XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer." F1000Research 9 (June 21, 2021): 1219. http://dx.doi.org/10.12688/f1000research.26873.3.
Full textAbstract:
Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX from primary mammary tumours or after neoadjuvant treatment are still rare. This study aims to assess the feasibility to establish xenografts from tumour samples of patients with triple negative or luminal B breast cancer in neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a single-centre and prospective study. This feasibility pilot trial aims to produce xenografts from tumour samples of patients with triple negative or luminal B breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be enrolled and followed for 28 months. Additional blood samples will be taken as part of the study. Surgical specimens from post-NAC surgery, primary surgery or surgical excision of the metastases will be collected to establish PDX. Histomolecular characteristics of the established PDX will be investigated and compared with the initial histomolecular profile of the collected tumours to ensure that they are well-established. Ethics and dissemination: XENOBREAST belongs to category 2 interventional research on the human person. This study has been approved by the Sud Méditerranée IV – Montpellier ethics committee. It is conducted notably in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study data and findings will be published in peer-reviewed medical journals. We also plan to present the study and all data at national congresses and conferences. Registration: ClinicalTrials.gov ID NCT04133077; registered on October 21, 2019.
13
Manfredini, Fabio, Nicola Lamberti, Yuri Battaglia, Sofia Straudi, Martino Belvederi Murri, Maria Donadi, Giovanni Piva, et al. "A Personalized Patient-Centered Intervention to Empower through Physical Activity the Patient in the Dialysis Center: Study Protocol for a Pragmatic Nonrandomized Clinical Trial." Methods and Protocols 3, no. 4 (December 6, 2020): 83. http://dx.doi.org/10.3390/mps3040083.
Full textAbstract:
Sedentariness of patients affected by end-stage kidney disease (ESKD) expose them to high risk of unfavorable clinical outcomes. Exercise training is effective in improving physical function, quality of life (QoL) and long-term outcomes. However, the existing barriers related to patients, programs and dialysis staff limit patient participation and call for new strategies. This pragmatic nonrandomized trial will test the impact on ESKD population of an intervention proposed by an exercise facilitator regularly present in a dialysis center. The patient will be free to choose among three-month walking and/or resistance low-intensity training programs: (a) guided physical activity increase; (b) home-based exercise; (c) in-hospital (pre/post dialysis) supervised exercise; (d) performance assessment only. The first phase will define feasibility and the characteristics and preference of responders. The second phase will evaluate safety and patients’ adherence. Outcome measures will be collected at baseline, after three-month and at six-month follow-up. They will include: aerobic capacity, QoL, gait speed, strength, depression and long-term clinical outcomes (hospitalization and mortality). The trial was approved by the Area-Vasta Emilia-Romagna Centro Ethics Committee with approval number 48/2019. Written informed consent will be obtained from all participants. The results of the study will be presented in international congresses, published in peer-reviewed journals and communicated to the patient community. Registration details: Clinicaltrials.gov NCT04282616 [Registered:24/02/2020].
14
ZENETOS, A., S. KATSANEVAKIS, D. POURSANIDIS, F. CROCETTA, D. DAMALAS, G. APOSTOLOPOULOS, C. GRAVILI, E. VARDALA-THEODOROU, and M. MALAQUIAS. "Marine alien species in Greek Seas: Additions and amendments by 2010." Mediterranean Marine Science 12, no. 1 (March 11, 2011): 95. http://dx.doi.org/10.12681/mms.55.
Full textAbstract:
An update of the inventory of alien marine species from the coastal and offshore waters of Greece is presented. Records were compiled based on the existing scientific and grey literature, including the HCMR database of Greek alien species (ELNAIS), technical reports, scientific congresses, academic dissertations, websites, and unpublished/personal observations. 47 species were added to the inventory, including 34 invertebrates, one vertebrate (fish), three plants, eight protozoa, and one cyanobacterium. With the new records, the inventory of alien marine species of Greece now includes a total of 237 species (33 macrophytes, 131 invertebrates, 42 vertebrates, two bacteria and 29 protozoans). Among these, the presence of the gastropodHypselodoris infucata, the bivalvesDendrostrea frons and Septifer forskaliand the chondrichthyan Rhizoprionodon acutus is reported here for the first time. Based on molecular analysis, the occurrence of Bulla arabica in Greek waters is confirmed, and the suggestion that previous records of Bulla ampulla in the Mediterranean should be considered as misidentification of B. arabica is further supported. The acclimitization status of earlier records was revised in the light of new data, and thus the fishEnchelycore anatina, Seriola fasciata andTylerius spinosissimus, the red algaeHypnea cornuta and Sarconema scinaioides, the scyphomedusaCassiopea andromeda, the cephalopodSepioteuthis lessoniana, the nudibranchChromodoris annulata and the bivalvesGastrochaena cymbium andPseudochama corbieri were upgraded from casual records to established populations. The increased rate of introductions of warm water species confirms previous findings, which link the rate of introduction in the eastern Mediterranean to climate change.
15
Gagelmann, Nico, Francis Ayuketang Ayuk, Djordje Atanackovic, and Nicolaus Kroeger. "B Cell Maturation Antigen-Specific CAR T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis." Blood 134, Supplement_1 (November 13, 2019): 3113. http://dx.doi.org/10.1182/blood-2019-121967.
Full textAbstract:
Background Cellular immunotherapies represent an enormously promising strategy for relapsed/refractory multiple myeloma (RRMM). Chimeric antigen receptor (CAR) T cells targeting B cell maturation antigen (BCMA) have shown impressive results in early-phase clinical studies. Here, we summarize the current body of evidence on the role of anti-BCMA CAR T cell therapy for RRMM. Methods We performed a systematic literature review to identify all publicly available prospective studies. We searched Medline, Cochrane trials registry, and www.clinicaltrials.gov. To include the most recent evidence, meeting abstracts from international hematology congresses were added. A conventional meta-analysis was conducted using meta and metafor packages in R statistical software. Pooled event rates and 95% confidence intervals (CIs) were calculated using the inverse variance method within a random-effects framework. Main efficacy outcomes were overall response, complete response (CR), and minimal residual disease (MRD). Furthermore, relapse rates, progression-free survival, and overall survival were evaluated. In terms of safety, outcomes were cytokine release syndrome (CRS), neurotoxicity, and hematologic toxic effects. Results Fifteen studies comprising a total of 285 patients with heavily pretreated RRMM were included in quantitative analyses. Patients received a median of seven prior treatment lines (such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, stem cell transplantation) which included autologous stem cell transplantation in 90% of patients. The median age of patients was 59 years and median follow-up duration ranged from 1.1 to 11.3 months. Most studies used 4-1BB (or CD137), a member of the TNF receptor superfamily, as an activation-induced T-cell costimulatory molecule. Most studies used fludarabine and cyclophosphamide for lymphodepletion while one study used busulfan and cyclophosphamide and one study used cyclophosphamide only. Most studies used the former Lee criteria for CRS grading. Anti-BCMA CAR T cells resulted in a pooled overall response of 82% (95% CI, 74-88%). The pooled proportion of CR in all evaluable patients was 36% (95% CI, 24-50%). Within responders, the pooled proportion of MRD negativity was 77% (95% CI, 67-85%). Higher dose levels of infused CAR+ cells were associated with higher overall response rates resulting in a pooled proportion of 88% (95% CI, 78-94%). In addition, peak CAR T cell expansion appeared to be associated with responses.The presence of high-risk cytogenetics appeared to be associated with lower overall response rates resulting in a pooled proportion of 68% (95% CI, 47-83%). The presence of extramedullary disease at time of infusion did not influence outcome and was associated with similar response rates compared with RRMM patients who did not have extramedullary disease, resulting in a pooled proportion of 78% (95% CI, 47-93%). The pooled relapse rate of all responders was 45% (95% CI, 27-64%) and the median progression-free survival was 10 months. In terms of overall survival, pooled survival rates were 84% (95% CI, 60-95%) at last follow-up (median, 11 months). In terms of safety, the pooled proportion of CRS of any grade was 69% (95% CI, 51-83%). Notably, the pooled proportions of CRS grades 3-4 and neurotoxicity were 15% (95% CI, 10-23%) and 18% (95% CI, 10-31%). Peak CAR T cell expansion appeared to be more likely in the setting of more severe CRS in three studies. Most hematologic toxic effects of grade 3 or higher were neutropenia (85%), thrombocytopenia (70%), and leukopenia (60%). Conclusion Anti-BCMA CAR T cells showed high response rates, even in high-risk features such as high-risk cytogenetics and extramedullary disease at time of CAR T cell infusion. Toxicity was manageable across all early-phase studies. However, almost half of the patients who achieved a response eventually relapsed. Larger studies with longer follow-up evaluating the association of response and survival are needed. Disclosures Ayuk: Novartis: Honoraria, Other: Advisory Board, Research Funding. Kroeger:Medac: Honoraria; Sanofi-Aventis: Honoraria; Neovii: Honoraria, Research Funding; Riemser: Research Funding; JAZZ: Honoraria; Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; DKMS: Research Funding.
16
Barab, Jordan. "104th Congress, R.I.P." NEW SOLUTIONS: A Journal of Environmental and Occupational Health Policy 7, no. 2 (August 1997): 4–9. http://dx.doi.org/10.2190/ns7.2.b.
Full text
17
Howlett, Christina, Daniel J. Landsburg, Elise A. Chong, Sonya J. Snedecor, Stephen J. Schuster, Tina Marie Green, Jonathon B. Cohen, et al. "Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis." Blood 124, no. 21 (December 6, 2014): 3056. http://dx.doi.org/10.1182/blood.v124.21.3056.3056.
Full textAbstract:
Abstract Introduction: Double-hit lymphoma (DHL), characterized by the presence of both c-Myc and BCL-2 rearrangements, is an aggressive B-cell non-Hodgkin's lymphoma (NHL) that is clearly associated with an inferior prognosis compared to standard risk DLBCL. DHL pts do poorly when treated with R-CHOP and typically cannot be salvaged once relapsed. Studies examining the treatment of DHL pts have been small and there is a lack of consensus in the lymphoma community as to whether DHL pts benefit from dose-escalated chemotherapy regimens in the front-line setting. To address this question, we generated pooled, meta-analytic estimates of the effectiveness of dose-escalated approaches vs. standard dose immunochemotherapy in prolonging overall survival (OS) and progression-free survival (PFS) in newly diagnosed DHL pts. Methods: DHL was defined by the presence of c-Myc rearrangement (FISH) in combination with BCL2 rearrangement (FISH) in pts with DLBCL or transformed follicular lymphoma. Treatment regimens included dose intensive (DI; R-Hyper-CVAD, R-CODOX-M/IVAC), intermediate dose [Dose adjusted (DA)-R-EPOCH], or standard dose (R-CHOP). PubMed, Embase, and abstracts at 3 specific congresses from 1/2009 to 6/2014 were searched using terms lymphoma with DHL, dual hit, dual translocation, double-hit, or myc and bcl2. Randomized controlled trials and observational studies evaluating treatment of DHL were eligible for inclusion. Studies of ≤ 10 DHL pts were excluded. Data were collected from study authors or extracted from publications as the proportions of pts surviving at specific follow-up times or individual event times. Data were synthesized to estimate the hazard ratios of higher-dose treatments relative to R-CHOP using a Weibull proportional hazards model within a Bayesian meta-analysis framework. Results: The initial search yielded 996 hits and 57 congress abstracts. After independent review by three investigators, 11 studies examining 401 pts were included in the analysis. Pts were treated with either R-CHOP (n=180), DA-R-EPOCH (n=91), or DI regimen (n=130) in the front-line setting. There were no significant differences in baseline characteristics of pts between included studies or across treatment regimens (median age at diagnosis 60 years, median Ki-67 88%, 53% IPI ≥ 3). The estimated median (and 95% credible intervals [CrIs; the Bayesian analog to confidence intervals]) OS and PFS for the entire cohort were 27.8 (15.1-48.5) and 20.5 (10.9-36.0) months. No significant differences in OS (n=374) were observed among any of the treatments (estimated med OS: R-CHOP, DA-R-EPOCH and DI were 24.2, 37.5, and 29.5 months, respectively, Figure A). Estimated hazard ratios (HR) of OS were 0.77 (95% CrI: 0.50-1.11) for DA-R-EPOCH and 0.90 (95% CrI: 0.62-1.25) for DI relative to R-CHOP. The PFS (n=357) among pts receiving DA-R-EPOCH (HR 0.64, 95% CrI: 0.42-0.92) or DI (HR 0.75, 95% CrI: 0.51-1.05) was similar and DA-R-EPOCH demonstrated significant improvement over R-CHOP (estimated med PFS: R-CHOP, DA-R-EPOCH and DI of 13.9, 27.8, and 21.9, respectively, Figure B). Conclusions: In the largest study and first meta-analysis of treatment outcomes in DHL pts, we have demonstrated that dose-escalated chemotherapy was associated with a significant increase in PFS (particularly DA-R-EPOCH) which did not translate into an OS advantage. This suggests DHL is a disease of chemotherapy resistance. One can consider the use of dose-escalated front-line therapies as they can lead to a PFS advantage and that consolidation strategies should be developed to reduce the likelihood of relapse. These results highlight (1) outcomes remain poor for DHL pts regardless of the intensity of R-chemotherapy induction (2) the need for routine screening for MYC and BCL2 by FISH in DLBCL pts with high-risk features and (3) the need for prospective induction and consolidation strategies that incorporate our growing understanding of the biological basis of DHL such as combinations of novel targeted therapies and/or upfront consolidation with CAR-T-cells. Figure. Weibull meta-analysis estimates of OS (A) and PFS (B) with hazard ratios and 95% credible intervals; *in Bayesian analyses, statistically meaningful differences between treatments are not assessed by P-values, but by whether the CrI contains the value 1, indicating the probability of lower risk of event is <97.5%. Figure. Weibull meta-analysis estimates of OS (A) and PFS (B) with hazard ratios and 95% credible intervals; *in Bayesian analyses, statistically meaningful differences between treatments are not assessed by P-values, but by whether the CrI contains the value 1, indicating the probability of lower risk of event is <97.5%. Disclosures Cohen: Pharmacyclics: Consultancy; Seattle Genetics: Consultancy; BMS: Research Funding; Janssen: Research Funding. Mato:Celgene: Honoraria, Research Funding.
18
Drummond, F. "Congress content." Veterinary Record 125, no. 13 (September 23, 1989): 356. http://dx.doi.org/10.1136/vr.125.13.356-b.
Full text
19
Cullen, M. "Annual Congress." British Journal of Sports Medicine 30, no. 3 (September 1, 1996): 269–70. http://dx.doi.org/10.1136/bjsm.30.3.269-b.
Full text
20
Mills, Russell W. "Congressional modification of benefit-cost analysis as a vehicle for particularized benefits and a limitation on agency discretion: the case of the federal contract tower program." Journal of Benefit-Cost Analysis 4, no. 3 (December 1, 2013): 301–33. http://dx.doi.org/10.1515/jbca-2013-0014.
Full textAbstract:
The literature on Congressional control of the bureaucracy has examined how members of Congress pursue strategies such as oversight, the limitation of discretion in legislation [Moe, T. (1989). The politics of bureaucratic structure. In J. E. Chubb & P. E. Peterson (Eds.), Can the Government Govern? Washington, DC: Brookings Institution); Huber, J. D., & Shipan, C. R. (2002). Deliberate discretion: The institutional foundations of bureaucratic autonomy. New York: Cambridge University Press], and the use of tools such as administrative procedures [McCubbins, M., & Schwartz, T. (1984). Congressional oversight overlooked: police patrols vs. fire alarms. American Journal of Political Science, 21(1), 165–179; McCubbins, M., Noll, R., & Weingast, B. (1987). Administrative procedures as instruments of political control. Journal of Law, Economics, and Organization, 3, 243–277] and limitation riders [MacDonald, J. A. (2010). Limitation riders and congressional influence over bureaucratic policy decisions. American Political Science Review, 104 (November), 766–782] to exert influence over executive agency decision making. One area where Congress has attempted to exert control over agency decision-making is through the legislative modification of one of the most common bureaucratic decision-making tools: benefit-cost analysis (BCA). While scholars have examined political influence in agency regulatory impact analysis BCAs for proposed rules [Shapiro, S., & Morrall III, J. F. (2012). The triumph of regulatory politics. Benefit-cost analysis and political salience. Regulation and Governance, 6(2), 189–206], there has been a lack of examination of Congressional modification of agency BCA processes to justify and protect particularized [Mayhew, D. (1974). Congress: The electoral connection. New Haven, CT: Yale University Press] infrastructure projects in their districts. This paper will examine the effect of Congressional control over agency BCA processes to secure particularized benefits by developing an in-depth case study of the Federal Contact Tower Program (FCTP) operated by the Federal Aviation Administration (FAA) that examines the political and public management implications of Congress’s limitation of the FAA’s autonomy to operate the FCTP under current benefit-cost guidance. Building upon the literature on particularized benefits and Congressional delegation, the results of this study indicate that members of Congress use BCA processes to insulate infrastructure projects in their districts by restricting the ability of agencies to optimize program effectiveness.
21
Szweda, Roy. "B&B and the world congress on biosensors 1994." Biosensors and Bioelectronics 9, no. 2 (January 1994): i. http://dx.doi.org/10.1016/0956-5663(94)80092-8.
Full text
22
McClellan, R. O. "Science in Congress: Unnecessary conflict." Science 349, no. 6247 (July 30, 2015): 486. http://dx.doi.org/10.1126/science.349.6247.486-b.
Full text
23
CRAWFORD, M. "Congress to Weigh Animal Patents." Science 236, no. 4805 (May 29, 1987): 1058. http://dx.doi.org/10.1126/science.236.4805.1058-b.
Full text
24
CRAWFORD, M. H. "Congress Caps Grant Overhead Charge." Science 245, no. 4919 (August 18, 1989): 705. http://dx.doi.org/10.1126/science.245.4919.705-b.
Full text
25
Nascimento, Artur Roberto do, Emanuel Junqueira, and Gilberto de Andrade Martins. "Pesquisa acadêmica em contabilidade gerencial no Brasil: análise e reflexões sobre teorias, metodologias e paradigmas." Revista de Administração Contemporânea 14, no. 6 (December 2010): 1113–33. http://dx.doi.org/10.1590/s1415-65552010000700008.
Full textAbstract:
O trabalho teve por objetivo identificar e analisar as características epistemológicas da produção acadêmica da pesquisa em contabilidade gerencial no Brasil. Realizou-se uma pesquisa empírico-analítica com técnicas de análise bibliométrica e de conteúdo dos trabalhos do Congresso da Associação Nacional do Programas de Pós-Graduação em Ciências Contábeis [ANPCONT] de 2007 e 2008, Congressos de Contabilidade e Controladoria da Universidade de São Paulo [USP] e Encontros Nacionais da Associação Nacional de Pós-Graduação e Pesquisa em Administração [ANPAD] dos anos de 2005 a 2008, perfazendo um total de 287 trabalhos. Os resultados indicam: (a) baixa utilização de referências que abordem as teorias da contabilidade gerencial, baixa incidência de referências a artigos publicados em periódicos internacionais e alta idade média dos trabalhos citados, 10 anos; (b) as estratégias de pesquisa se concentram em pesquisas de campo (38%), levantamentos descritivos (16%), ou trabalhos documentais (9%), sem geração de teorias substantivas ou trabalhos de natureza explicativa; (c) em relação às teorias, observa-se que 83% dos trabalhos se baseiam somente em conceitos contábeis ou legislação, enquanto 17% utilizam teorias da economia, sociologia ou psicologia; (d) em relação aos paradigmas, observa-se que a maioria segue o funcionalista (97%), e apenas 3% seguiram paradigmas críticos/interpretativos.
26
Campbell, M. "Join the AMA Women Physicians Congress." JAMA: The Journal of the American Medical Association 280, no. 7 (August 19, 1998): 670—b—670. http://dx.doi.org/10.1001/jama.280.7.670-b.
Full text
27
Lalević-Vasić, Bosiljka M., and Marina Jovanović. "History of dermatology and venereology in Serbia – part IV/2: Dermatovenereology in Serbia from 1919 – 1945, part 2." Serbian Journal of Dermatology and Venerology 2, no. 2 (May 1, 2010): 66–72. http://dx.doi.org/10.2478/v10249-011-0024-x.
Full textAbstract:
Abstract After the First World War, Serbia was facing the lack of hospitals and physicians, and organization of the health care system was a real challenge. Both problems were closely associated with dermatovenereology. Between the two world wars, a great contribution to the development of Serbian dermatovenereology as a current discipline was given by Prof. Dr. Đorđe Đorđević, who was the first director of the Clinic for Skin and Venereal Diseases in Belgrade (1922 - 1935), and by his closest associate Prof. Dr. Milan Kićevac (1892 - 1940) who was his successor at the position of the director of the Clinic (1935 - 1940). In 1922, Prof. Dr. Đorđe Đorđević was the founder of two institutions significant for Serbian dermatovenereology: Clinic for Skin and Venereal Diseases, where he also acted as a director, and the Department of Dermatovenereology at the School of Medicine in Belgrade, where he was the first teacher of dermatovenereology. In 1927, Prof. Dr. Đorđe Đorđević initiated the foundation of the Dermatovenereology Section of the Serbian Medical Society, and he and his associate and successor, Prof. Dr. Milan Kićevac were the main organizers of the Association of Dermatovenereologists of Yugoslavia. With this Association, all other regional dermatovenereology sections in the County became parts of the Pan-Slavic Dermatovenereology Association. Prof. Dr. Đorđe Đorđević and Prof. Dr. Milan Kićevac also organized the First, Second and the Third Yugoslav Dermatovenereology Congresses (1927, 1928, and 1929), and in 1931, the Second Congress of Pan-Slavic Dermatovenereology Association. Their teamwork resulted in legislation concerned with health care, eradication of venereal diseases and prostitution, and finally with setting the foundation for professional and scientific dermatovenereology in Serbia. Prof. Đ. Đorđević investigated current problems of venereal diseases and organized professional expeditions in Serbia and Montenegro studying the expansion of syphilis. However, in his experimental work, Prof. M. Kićevac investigated photo-dermatoses and the IV venereal disease, at the same time pointing to immunological phenomena in streptococcal and staphylococcal infections. Dr. Vojislav Mihailović (1879 - 1949) was a significant figure in Serbian dermatovenereology and acted as the Chief of the Department of Skin and Venereal Diseases within the General Public Hospital in Belgrade. His scientific papers and books on the history of dermatovenereology and general medicine had a great impact on the Serbian dermatovenereology. His books dealing with the history of dermatovenereology: “The History of Venereal Diseases till 1912” and “Out of the History of Sanitary Health Care in the Rebuilt Serbia from 1804 - 1860”. Associate Professor Dr. Sava Bugarski (1897 - 1945), a student of Prof. Dr. Kićevac and later the director of Clinic for Skin and Venereal Diseases in Belgrade (1940 - 1945), was engaged in the field of experimental dermatovenereology. Dr. Jovan Nenadović (1875 - 1952), one of the most eminent physicians in Novi Sad, took part in the foundation and work of the Dermatovenereology Section of the Serbian Medical Society as well as its honorary life president. In 1919, he founded the Dermatovenereology Department within the Novi Sad Hospital, as well as an Outpatient Dermatovenereology Clinic, outside the Hospital, although he was the director of both institutions. In the period between the two world wars, among the most prominent physicians of the Military Sanitary Headquarters who contributed the development of dermatovenereology were the chiefs of the Dermatovenereology Department of the General Military Hospital in Belgrade: Major, later on, Brigadier General, Dr. Božidar Janković (1874 - 1936), and the Sanitary Brigadier General, Dr. Milivoje Pantić (1885 - 1959). Dr. B. Janković wrote important professional papers, among which the following are most significant: ”Fight against Venereal Diseases in the Army” and ”Treatment of Syphilis with Silber-Salvarsan.” Distinguished physicians of the military sanitary service, such as Dr. Petar Davidović, made significant contributions to the work of civilian dermatovenereology institutions of that time. In 1921, Dr. Petar Davidović was the director of the newly founded Venereal Department of the Niš Public Hospital, which was on a high professional level.
28
CRAWFORD, M. "Congress Urged to Change Patterns of Research Support." Science 232, no. 4750 (May 2, 1986): 571–72. http://dx.doi.org/10.1126/science.232.4750.571-b.
Full text
29
CRAWFORD, M. H. "Congress to Extend R&D Tax Credits." Science 246, no. 4934 (December 1, 1989): 1116. http://dx.doi.org/10.1126/science.246.4934.1116-b.
Full text
30
Georgescu, Nicolae. "The history of orthopedics and traumatology in Iasi." Jurnalul de Chirurgie 17, no. 1 (April 20, 2021): 56–62. http://dx.doi.org/10.7438/jsurg.2021.01.08.
Full textAbstract:
In Iasi, Orthopedics-Traumatology later appeared as a distinct specialty. In a first stage, orthopedics developed in surgical clinics - the period of surgical clinics (1879-1970). In each surgical clinic there were surgeons who dedicated themselves to orthopedic pathology: Radu Dimitrie, Theodor Căpățînă (Surgery I), Filimon Cicerone, Eusebiu Neagoe, Iulian Grădinaru (Surgery II), Paul Trosc (Surgery III). In 1967, at the Charity Hospital, two surgical services were carried out: The Surgery and Children's Orthopedic Clinic (Th. Economu) and the Osteoarticular Tuberculosis Clinic (A. Berneaga). Also, this year, 1970, in Iasi, the construction of a new medical unit will be completed - the Children's Hospital where the Clinic of Pediatric Surgery and Orthopedics will be moved. The Charity Hospital is disbanded and the Emergency Clinical Hospital will be established on the site of the former establishment. A second period begins - the transition period (1970-1983) - characterized by the search for optimal solutions, which involved changes and temporary until the establishment of orthopedic clinics. The newly established unit, the Emergency Clinical Hospital, was designed to include three departments: General Surgery IV (I. Jitaru), Medical Clinic (G. Popa) and an Orthopedics and Traumatology Clinic (conf. Gh. Floareș). This clinic treated all surgical pathology of orthopedics, traumatology and had didactic activity with fourth year students. The Orthopedics-Traumatology Department had 40 beds. There is also an Orthopedics-Traumatology department, with 40 beds, located in the Dr. C. I. Parhon Hospital run first by A. Berneaga and then by P. Trosc. Dimitrie Radu, Iulian Grădinaru and G. Herescu worked in this department. A new Recovery Hospital appears in Iasi. The new hospital also has an Orthopedics-Traumatology department (with 111 beds) where the orthopedics department will be transferred from Parhon Hospital. In 1983, Professor Gh. Floareș opted to move the clinic from the Emergency Hospital to the new Rehabilitation Hospital. At the Emergency Hospital there remains an Orthopedics-Traumatology Department staffed by a single doctor - Nicolae Georgescu who will develop a new team, which also have teaching activity: T. Cozma, L. Stratan, P. Sîrbu, Ovidiu Alexa, Paul Corlaci, Cezar Popescu. There are eight resident doctors (Elena Glod, Luminița Lăbușcă, Victor Pencu, G. Ghinoiu, C. Nanu, T. Bunescu, R. Malancea, L. Pacu). During this period (1992-1996) a basic A.O. course was organized in Iași. internationally, on which occasion many orthopedists are persuaded to routinely use modern means of osteosynthesis. Two more doctors come in this clinic: B. Puha, R. Asaftei, D. Cionca and A. Ciubara. After 1989, the ATOM was born: The Association of Traumatologists and Orthopedists of Moldova, congresses and postgraduate courses are organized. In 2012 the Orthopedic Clinic moved to the St. Spiridon Emergency Clinical Hospital (Prof. Ovidiu Alexa). The orthopedic clinic at the Recovery Hospital treats chronic osteoarticular pathology (prof Paul Sirbu).
31
Smith, R. "ACTA 24th International Congress of Ophthalmology, San Francisco, 1982." British Journal of Ophthalmology 69, no. 11 (November 1, 1985): 871. http://dx.doi.org/10.1136/bjo.69.11.871-b.
Full text
32
Carvalho, Rosana Areal de, and Raphael Ribeiro Machado. "Primitivo Moacyr e a produção historiográfica: entre o modus operandi do IHGB e a chancela do INEP." Acta Scientiarum. Education 38, no. 4 (September 14, 2016): 355. http://dx.doi.org/10.4025/actascieduc.v38i4.28147.
Full textAbstract:
Tendo como premissa a intencionalidade da produção historiográfica, articulada à condição científica aplicada à educação pelos signatários do Manifesto de 1932, buscamos apontar elementos para melhor compreender a publicação dos livros de Primitivo Moacyr no complexo cenário das décadas de 30 e 40 do século XX no Brasil. Sob os auspícios do modus operandi do Instituto Histórico e Geográfico Brasileiro - IHGB, Moacyr produziu uma história da educação divulgada em congressos históricos e publicada pela Companhia Editora Nacional. Em seguida, vinculou-se como pesquisador colaborador ao Instituto Nacional de Estudos Pedagógicos - INEP, publicando vários volumes pela Imprensa Oficial, alcançando a chancela pública. Para intervir, reformar ou revolucionar a educação brasileira, era preciso conhecer as ações já impetradas e recolher, sistematicamente, as experiências educacionais. Esta foi a meta perseguida com a criação do INEP, para a qual a contribuição de Moacyr foi lapidar. Concluímos que Moacyr inaugurou uma escrita da história da educação brasileira com as pesquisas arquivísticas.
33
Melo, Chagas. "O Congresso Nacional e o seu Funcionamento." Revista do Serviço Público 96, no. 4 (October 18, 2017): 38–42. http://dx.doi.org/10.21874/rsp.v0i4.2852.
Full textAbstract:
O poder Legislativo é exercido pelo Congresso Nacional, que se compõe da Câmara dos Deputados e do Senado Federal. São condições de elegibilidade para o Congresso Nacional: a) ser brasileiro nato ou filho de brasileiro ou brasileira, nascidos no estrangeiro, se os pais estiverem a serviço do Brasil, ou, não o estando, se vierem a residir no pais. Neste caso, atingida a maioridade deverão, para conservar a nacionalidade brasileira, optar por ela, dentro de 4 anos; b) estar no exercício dos direitos políticos; e c) ter idade superior a 21 anos para a Câmara Federal e 35 para o Senado Federal. De acordo com a Constituição, portanto, os naturalizados não podem ser eleitos para o Congresso Nacional, o que nos parece uma injustiça, devendo, no nosso entender, ser alterada a Constituição em seu artigo 38, para dar aos naturalizados condições de elegibilidade ao Congresso Nacional.
34
Zernig, Gerald. "Advice from a seasoned congress tourist." Lancet 342, no. 8875 (October 1993): 876. http://dx.doi.org/10.1016/0140-6736(93)92741-b.
Full text
35
Friedman, Gerald. "The First Half-Century of the International Association of Sedimentologists (IAS) 1952-2002." Earth Sciences History 23, no. 2 (January 1, 2004): 257–77. http://dx.doi.org/10.17704/eshi.23.2.8462u755316h2904.
Full textAbstract:
"On 1 September 1948, directly after the closing of the 18th International Geological Congress in London, UK, the British sedimentary petrologists, headed by P. Allen, arranged a meeting for the sedimentary petrologists who had participated in the Congress. P. Allen raised the following points for discussion: (a) is some sort of a international union in sedimentary petrology desirable? (b) Should some kind of international meeting of sedimentary petrologists be held regularly in the future?"
36
Paiva, Geraldo José De, and Fatima Regina Machado. "Congresso IAPR 2017 em Hamar, Noruega." REVER - Revista de Estudos da Religião 17, no. 3 (December 24, 2017): 203. http://dx.doi.org/10.23925/1677-1222.2017vol17i3a14.
Full textAbstract:
O Congresso da Associação Internacional de Psicologia da Religião (IAPR) 2017, realizado em Hamar, Noruega, de 21 a 24 de agosto, congregou pesquisadores de 29 países. Este breve relatório: (a) descreve as atividades realizadas durante o Congresso; (b) resume os temas gerais apresentados pelos palestrantes convidados; e (c) aponta os temas de pesquisa discutidos em comunicações paralelas e sessões de pôsteres e, deste modo, oferece uma visão geral do desenvolvimento de estudos da Psicologia da Religião em diferentes países em suas particularidades e pontos comuns.
37
Dunn, J. P. "Peter T. Rohrbach. The Largest Event: A Library of Congress Resource Guide for the Study of World War II. Washington, D.C.: Library of Congress, 1994. 137 pp." OAH Magazine of History 11, no. 1 (September 1, 1996): 44–45. http://dx.doi.org/10.1093/maghis/11.1.44-b.
Full text
38
Daniel Cohen. "Eighth congress of the European Economic Association." Journal of Mathematical Economics 21, no. 6 (January 1992): 609. http://dx.doi.org/10.1016/0304-4068(92)90030-b.
Full text
39
Muckle, D. S. "Science and Football. Proceedings of 1st World Congress of Science and Football." British Journal of Sports Medicine 23, no. 3 (September 1, 1989): 197–98. http://dx.doi.org/10.1136/bjsm.23.3.197-b.
Full text
40
Sánchez Martínez, José Said. "Los congresos locales y la política de gasto, 2000-2012." Foro Internacional 56, no. 226 (October 1, 2016): 1019. http://dx.doi.org/10.24201/fi.v56i226.2380.
Full textAbstract:
A partir del primer gobierno dividido se ha demostrado una mayor actividad de la Cámara de Diputados en el diseño del presupuesto de egresos. En contraparte, a nivel subnacional no sólo se desconoce si los congresos locales participan en el diseño de la política del gasto, sino también si el gobierno dividido tiene un efecto sobre la conducta de estos órganos. A partir de datos de tipo panel, esta investigación tiene dos objetivos: a) mostrar el grado de participación de los congresos locales en el diseño del presupuesto estatal; y b) probar si el gobierno dividido tiene un efecto sobre esta actividad.
41
Sánchez Martínez, José Said. "Los congresos locales y la política de gasto, 2000-2012." Foro Internacional 56, no. 4 (October 1, 2016): 1019. http://dx.doi.org/10.24201/fi.v56i4.2380.
Full textAbstract:
A partir del primer gobierno dividido se ha demostrado una mayor actividad de la Cámara de Diputados en el diseño del presupuesto de egresos. En contraparte, a nivel subnacional no sólo se desconoce si los congresos locales participan en el diseño de la política del gasto, sino también si el gobierno dividido tiene un efecto sobre la conducta de estos órganos. A partir de datos de tipo panel, esta investigación tiene dos objetivos: a) mostrar el grado de participación de los congresos locales en el diseño del presupuesto estatal; y b) probar si el gobierno dividido tiene un efecto sobre esta actividad.
42
Restori, M., and D. McLeod. "Documenta Ophthalmologica Proceedings Series 38. Ophthalmic Ultrasonography. Proceedings of the 9th SIDUO Congress." British Journal of Ophthalmology 69, no. 9 (September 1, 1985): 714–15. http://dx.doi.org/10.1136/bjo.69.9.714-b.
Full text
43
Sheehan, Jennifer K. "Bettina Wagner and Marcia Reed, eds. Early Printed Books as Material Objects. Berlin: De Gruyter Saur, 2010. xii, 367p. ISBN 9783110253245. $150.00." RBM: A Journal of Rare Books, Manuscripts, and Cultural Heritage 13, no. 1 (March 1, 2012): 69–70. http://dx.doi.org/10.5860/rbm.13.1.372.
Full textAbstract:
This book consists of the proceedings from a preconference organized by the Rare Books and Manuscripts Section of the International Federation of Library Associations and Institutions (IFLA), held in Munich 19–21 August 2009 as a satellite meeting to IFLA’s annual congress in Milan, Italy. In the Introduction, Wagner sets the stage for the work included in this collection of presented papers. Although multiple copies of early printed editions may survive to the present day, Wagner emphasizes the importance of early printed books as individual objects, each with unique characteristics that distinguish it from all other copies printed in the . . .
44
Shaw, M. "Clinical Neurosurgery Vol 33. (Proceedings of the Congress of Neurological Surgeons Honolulu, Hawaii, 1985.)." Journal of Neurology, Neurosurgery & Psychiatry 50, no. 8 (August 1, 1987): 1087–88. http://dx.doi.org/10.1136/jnnp.50.8.1087-b.
Full text
45
Delorenzo Neto, A. "O Congresso Internacional de Municipalidades de Haia." Revista do Serviço Público 79, no. 01 (January 17, 2020): 73–77. http://dx.doi.org/10.21874/rsp.v79i01.4218.
Full textAbstract:
Rea l i z o u -s e em Haia de 12 a 18 de junho de 1957 o XIII CongressoInternacional de Municipalidades promovido pela “Unicn International desVilles et Pouvoirs Locaux” sob o alto patrocínio do Governo de Sua Majestadea Rainha dos Países Baixos.O Congresso desenvolveu-se em três seções: duas relativas ao temageral — “La Ville et la Campagne”, (desmembradas, respectivamente, em“section-Ville” e “section-Campagne” ), e uma especializada, de “Assuntoseuropeus” . Nesta ordem metodológica, os subtemas oficiais foram cs seguintes:1 — Os problemas da expansão urbana-.a) As cidades em via de expansão,b ) A industrialização das regiões rurais,c) O problema do congestionamento da circulação no centro dascidades.II — O desenvolvimento da vida comunitária nas zonas rurais.III — Os governos municipais e a integração econômica européia:a) A criação de um mercado comum e suas repercussões econômicase sociais,b ) Os problemas sociais suscitados pela migração da mão-de-obra,c) O problema da habitação na Europa.
46
Santamaría García, Antonio. "Temas y controversias del debate histórico internacional reciente en torno a la industria azucarera." América Latina en la Historia Económica 13, no. 1 (January 1, 2006): 4. http://dx.doi.org/10.18232/alhe.v13i1.370.
Full textAbstract:
Este artículo revisa la evolución reciente del debate internacional sobre la historia de la industria azucarera. Tras los congresos organizados por B. Albert y A. Graves en el Reino Unido en la década de 1980, la discusión sufrió un impasse, pero se ha recuperado en los últimos años. Usando las ponencias presentadas en dichos congresos y las contribuciones a eventos y obras colectivas realizados y publicados en los últimos siete años, examinamos cómo han variado las preocupaciones y los enfoques. En general, se ha mantenido el interés por determinados temas de especial relevancia, como los cambios tecnológicos, y se han incorporado nuevos aspectos y métodos de investigación que enriquecen considerablemente el conocimiento.
47
Sinclair, Leslie. "Congress Speeds Funds to FDA to Continue Pace of Drug Approvals." Psychiatric News 47, no. 13 (July 6, 2012): 4b—18. http://dx.doi.org/10.1176/pn.47.13.psychnews_47_13_4-b.
Full text
48
Bassey, E. J. "Active aging in the new millennium: fifth world congress on physical activity, aging, and sports." British Journal of Sports Medicine 34, no. 1 (February 1, 2000): 73—b—5. http://dx.doi.org/10.1136/bjsm.34.1.73-b.
Full text
49
Harris, Paul W. "Racial Identity and the Civilizing Mission: Double-Consciousness at the 1895 Congress on Africa." Religion and American Culture: A Journal of Interpretation 18, no. 2 (2008): 145–76. http://dx.doi.org/10.1525/rac.2008.18.2.145.
Full textAbstract:
AbstractThe Congress on Africa was held in Atlanta, Georgia, in December 1895 as part of a campaign to promote African American involvement in Methodist missions to Africa. Held in conjunction with the same exposition where Booker T. Washington delivered his famous Atlanta Compromise address, the Congress in some ways shared his accommodationist approach to racial advancement. Yet the diverse and distinguished array of African American speakers at the Congress also developed a complex rationale for connecting the peoples of the African diaspora through missions. At the same time that they affirmed the need for “civilizing” influences as an indispensable element for racial progress, they also envisioned a reinvigorated racial identity and a shared racial destiny emerging through the interactions of black missionaries and Africans. In particular, the most thoughtful participants in the Congress anticipated the forging of a black civilization that combined the unique gifts of their race with the progressive dynamics of Christian culture. These ideas parallel and likely influenced W. E. B. Du Bois's concept of double-consciousness. At a time when the missionary movement provided the most important source of awareness about Africa among African Americans, it is possible to discern in the proceedings of the Congress on Africa the glimmerings of a new pan-African consciousness that was destined to have a profound effect on African American intellectual life in the twentieth century.
50
BANDYOPADHYAY, SEKHAR. "Transfer of Power and the Crisis of Dalit Politics in India, 1945–47." Modern Asian Studies 34, no. 4 (October 2000): 893–942. http://dx.doi.org/10.1017/s0026749x00003875.
Full textAbstract:
Ever since its beginning, organized dalit politics under the leadership of Dr B. R. Ambedkar had been consistently moving away from the Indian National Congress and the Gandhian politics of integration. It was drifting towards an assertion of separate political identity of its own, which in the end was enshrined formally in the new constitution of the All India Scheduled Caste Federation, established in 1942. A textual discursive representation of this sense of alienation may be found in Ambedkar's book, What Congress and Gandhi Have Done to the Untouchables, published in 1945. Yet, within two years, in July 1947, we find Ambedkar accepting Congress nomination for a seat in the Constituent Assembly. A few months later he was inducted into the first Nehru Cabinet of free India, ostensibly on the basis of a recommendation from Gandhi himself. In January 1950, speaking at a general public meeting in Bombay, organized by the All India Scheduled Castes Federation, he advised the dalits to co-operate with the Congress and to think of their country first, before considering their sectarian interests. But then within a few months again, this alliance broke down over his differences with Congress stalwarts, who, among other things, refused to support him on the Hindu Code Bill. He resigned from the Cabinet in 1951 and in the subsequent general election in 1952, he was defeated in the Bombay parliamentary constituency by a political nonentity, whose only advantage was that he contested on a Congress ticket. Ambedkar's chief election agent, Kamalakant Chitre described this electoral debacle as nothing but a ‘crisis’.